DE-BIOCORP
19.2.2020 18:02:08 CET | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization.
In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management.
This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration").
Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. Combining these two solutions offers to date the most powerful environment for diabetes digitalization and patient support. Together, we can simplify the often complex and confusing journey for patients starting on basal insulin. “
Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. For the community of diabetes, this integration is a powerful service platform that takes into account all the clinical and behavioral needs of patients. "
ABOUT ISAGE RX
iSage Rx, manufacturers of the iSage App, the first FDA 510(k)-cleared, prescription-only mobile application for the automated titration of all brands of basal insulin. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com .
ABOUT AMALGAM RX
Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management. Led by an experienced team of physicians, behaviorists, technologists, and digital health pioneers, Amalgam Rx strives to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease. Amalgam does this by partnering with leading life sciences companies to accelerate the R&D and commercialization of digital therapeutics. For more information, visit http://amalgamrx.com/ .
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
Follow us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005728/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
70% of Enterprise AI is Uncontrolled, Driving Hidden Risk, Cost and Slower ROI27.4.2026 10:00:00 CEST | Press release
Lenovo research highlights a growing AI execution gap as organizations struggle to control and operate AI across their environments AI is already being used across your organization, whether it has been formally approved or not. Employees are using AI with or without IT involvement, fueling the rise of ‘shadow AI’ across the enterprise, creating gaps in governance and control. This is no longer just an IT challenge. For Chief Information Security Officers, this shift is expanding the attack surface across devices, endpoints, and data flows, introducing unmanaged risk and increasing the likelihood of sensitive company data being exposed or accessed without proper controls. What this reveals is a growing AI execution gap: usage is accelerating, but control is not keeping pace. Based on a survey of 6,000 employees worldwide, Lenovo’s latest Work Reborn Report, Leading Your Workforce to Triumph with AI, finds that more than 70% of employees are using AI weekly, with up to one third operati
First Enterprise Quantum Computer Purchase in Japan: IQM to Deploy System to TOYO Corporation27.4.2026 08:00:00 CEST | Press release
First enterprise quantum computer purchase in Japan cements IQM's position as the global leader in deployed quantum computers The Radiance 20-qubit system will enable TOYO to explore various industry use cases, while advancing a hybrid quantum-HPC infrastructure. This will be the third quantum computer to be deployed by IQM in the Asia-Pacific region. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the purchase of its full-stack 20-qubit quantum computer by TOYO Corporation, marking the first enterprise quantum system deployment in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426053944/en/ (From Left): Toshiya Kohno, Representative Director, President and CEO of TOYO Corporation, and Jan Goetz, CEO & Co-founder of IQM Quantum Computers. The Radiance 20-qubit system will be made available in both on-premises and cloud environments and will be delivered by the end of 2
SAP and S3NS Accelerate Trusted Cloud Adoption in France With Thales as First Strategic Customer27.4.2026 08:00:00 CEST | Press release
Thales adopts SAP RISE private cloud edition on S3NS to transform its ERP (Enterprise Resource Planning) landscape and operationalize digital sovereignty at scale. By combining SAP’s enterprise applications and Business AI capabilities with S3NS’s trusted infrastructure, this partnership unlocks cloud adoption for highly regulated sectors, including public administration, aerospace and defense, and operators of vital and essential services. Thales (Euronext Paris: HO): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426644177/en/ Strategic partnership (c)S3NS A decisive step in scaling trusted cloud in Europe The strategic partnership between SAP and S3NS, the trusted cloud provider established by Thales and Google Cloud, will strengthen trusted cloud capabilities in France and support Europe’s growing demand for cloud business transformation. SAP RISE private cloud edition will be deployed by SAP Sovereign Cloud on S3NS’
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom